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Memory CD8+ T lymphocytes (CTLs) specific for antigenic peptides
derived from internal viral proteins confer broad protection against
distinct strains of influenza A virus (IAV). However, immune efficacy
can be undermined by the emergence of escape mutants. To deter-
mine how T-cell receptor (TCR) composition relates to IAV epitope
variability, we used ex vivo peptide–HLA tetramer enrichment and
single-cell multiplex analysis to compare TCRs targeted to the largely
conserved HLA-A*0201-M158 and the hypervariable HLA-B*3501-
NP418 antigens. The TCRαβs for HLA-B*3501-NP418+ CTLs varied
among individuals and across IAV strains, indicating that a range of
mutated peptides will prime different NP418-specific CTL sets. Con-
versely, a dominant public TRAV27/TRBV19+ TCRαβ was selected
in HLA-A*0201+ donors responding to M158. This public TCR
cross-recognized naturally occurring M158 variants complexed
with HLA-A*0201. Ternary structures showed that induced-fit mo-
lecular mimicry underpins TRAV27/TRBV19+ TCR specificity for the
WT and mutant M158 peptides, suggesting the possibility of uni-
versal CTL immunity in HLA-A*0201+ individuals. Combined with
the high population frequency of HLA-A*0201, these data poten-
tially explain the relative conservation of M158. Moreover, our
results suggest that vaccination strategies aimed at generating
broad protection should incorporate variant peptides to elicit
cross-reactive responses against other specificities, especially those
that may be relatively infrequent among IAV-primed memory CTLs.
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Preexisting CD8+ T-lymphocyte (CTL) immunity directed atpeptides derived from internal viral proteins is known to
confer protection against specific strains of influenza A virus (IAV)
(1–5). Recalled memory CTLs generated by seasonal variants can
also expedite virus elimination and host recovery following infection
with H1N1, H2N2, H3N2, H5N1, and H7N9 IAVs (2, 3, 6–9).
However, it is unclear why such cross-strain responses vary among
individuals. The ability of αβ T-cell receptors (TCRαβs) to recog-
nize antigenic epitopes from distinct IAVs and circumvent immune
escape relies on peptide sequence conservation and/or structural
homology (10–12). A detailed understanding of cross-strain reactivity
in relation to defined TCRαβ interactions may therefore inform the
rational development of a universal vaccine against IAV.
The conserved HLA-A*0201–restricted M158–66 (GILGFVFTL,
referred to hereafter as “M158”) (13) and variable HLA-B*07
superfamily-restricted NP418–426 (LPFERATVM, referred to here-
after as “NP418”) (10) peptides are the most immunogenic IAV
epitopes described in humans. The M158 epitope has remained
unchanged in seasonal and pandemic IAVs since 1918 (1, 8, 14,
15), although viruses with single-alanine-substitution mutants of
M158 generated by reverse genetics are replication competent (16).
Accordingly, the M158 peptide is an ideal vaccine candidate for >1
billion people globally who express HLA-A*0201. In contrast, the
NP418 epitope is hypervariable, encompassing >20 different natu-
rally occurring sequences. Analysis of HLA-B*07/B*35–restricted
NP418-specific CTLs in the wake of the 2009 pandemic revealed at
least two distinct responses to this prominent epitope (12).
In this study, we used ex vivo tetramer enrichment combined with
single-cell multiplex RT-PCR to dissect TCRαβ signatures within
CTL populations specific for the HLA-A*0201-M158 and HLA-
B*07/B*35-NP418 epitopes. Our data indicate that public A*0201-
TCRαβs use molecular mimicry to recognize distinct IAVs.
Results
Natural IAV M158 Variants Emerge in HLA-A2.1 Transgenic HHD Mice.
The HLA-A*0201–restricted M158 peptide is broadly conserved
across IAVs, although the M1-I2M and M1-L3W variants have
been found in 21% of H5N1 sequences (7). Using the influenza
resource database at the National Center for Biotechnology In-
formation, we aligned 1,000 full-length sequences representing
IAV subtypes infecting different species between 1918 and
2010 to conduct an in-depth validation of M158 conservation.
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Mutations were found in 8.2% of IAVs, and 11 distinct M158
substitutions were identified across all positions bearing the
C-terminal P8 and P9 residues (Table 1). The most frequent
M158 mutations occurred at the anchor residue (p2), accounting
for nearly 67% of all substitutions in the database (M1-I2M,
42%; M1-I2V, 23%; M1-I2T, 1.2%). Although these M158 var-
iants were detected mainly in avian IAVs (H2, H5, H6, H7, H9,
H11, and H13), 8 of the 82 mutant sequences were derived from
human isolates.
An established mouse model of IAV escape (17) was used to
probe the emergence of M158 mutants. As in humans, the M158
epitope is immunodominant in HLA-A2.1 HHD mice (Fig. S1 A
and B). Amino acid substitutions in M158 were encoded by viral
RNA extracted from the lungs of three of seven mice 15 d after
infection (Fig. S1 C–E), a lower mutation rate compared with the
immunodominant H2-DbNP366 epitope in WT B6 mice (17).
Engineered PR8 viruses carrying the M1-I2M, M1-F5L, M1-V6I,
and M1-F7Y mutations grew to similar titers in embryonated eggs
and MDCK cell cultures (Fig. S1 F and G). However, it remains
possible that subtle differences in viral fitness may counterselect
against M158 mutants in the natural setting. The absence of epitope-
specific immune pressure also may lead to the occurrence of viral
refugia in individual cases, a phenomenon widely recognized in the
ecology field.
Sequence variation within M158 therefore occurs in IAVs re-
covered from humans (8.2%) and from experimentally infected
HLA-A2.1 HHD mice (7.3%). However, unlike the frequent and
persistent mutations in NP418 (10), these M158 variants are not
readily fixed in circulating human IAVs. To determine whether
the contrasting patterns of viral variation within M158 and NP418
reflect immune selection, we undertook a detailed cellular and
molecular evaluation of the corresponding CTL responses.
HLA-A*0201-M158
+ CTLs Are Immunodominant and Recognize M158
Variants. Using direct ex vivo tetramer-based magnetic enrich-
ment (4, 18) to minimize selection bias, we analyzed CTL responses
specific for HLA-A*0201-M158 (A2-M158) and HLA-B*3501-
NP418 (B35-NP418) in individual subjects expressing both HLA-
A*0201 and HLA-B*3501 (Fig. 1 and Table S1). A2-M158
+ CTLs
were identified with a single conserved tetramer, and B35-NP418
+
CTLs were identified with a tetramer pool corresponding to the
main variants from 1918, 1934, 1947, 1980, and 2002 (12). The
A2-M158
+ CTL population was consistently larger (17 ± 9.2-fold)
than the B35-NP418
+ CTL population (Fig. 1A), which frequently
predominates in HLA-A*0201− donors (Fig. S2). Furthermore,
the polyclonal A2-M158
+ CTLs recognized all detected mutants,
although response frequencies varied and the M1-G4E mutant
was weakly immunogenic in five donors (Fig. 1B). Conversely, the
polyclonal B35-NP418
+ CTLs recognized a limited number of
variants (Fig. 1C), in line with previous reports of immune escape
(10, 12). Thus, M158-specific TCRs cross-react with a broader
spectrum of naturally occurring epitope variants compared with
NP418-specific TCRs. It is notable in this regard that NP418 variants
are often composite, incorporating up to three amino acid sub-
stitutions, whereas single mutations are more common in M158.
Dissection of A2-M158 and B35-NP418 TCRαβ Repertoires. Consistent
with previous reports (19–21), direct ex vivo single-cell sequencing
of the A2-M158
+ TCRαβ repertoire showed a heavy bias toward
T-cell receptor β variable 19 (TRBV19) use across all eight donors,
coupled with a dominant T-cell receptor α variable 27 (TRAV27)
segment in seven of eight donors (Fig. 2 A and B and Fig. S3 A
and B). The averaged frequency for TRBV19 was 91.6% (range
44–100%), compared with 49.2% (range 0–91%) for TRAV27.
The most common TCRαβ signature was the public clonotype
Table 1. Newly identified naturally occurring M158 peptide variants
GILGFVFTL Mutant No. % Source Year Subtype Strain
A- - - - - - - - G1A 1 0.1 Human 2009 H3N2 A/Tomsk/02/2009
W- - - - - - - - G1W 1 0.1 Swine 2005 H3N2 A/swine/Guangdog/01/2005
-V- - - - - - - I2V 19 1.9 Avian 1999–2008 H3N2, H5N1, H7N7, H7N2, H7N3,
H9N2, H2N1
A/Hanoi/TN405/2005
-M- - - - - - - I2M* 35 3.5 Avian 1999–2008 H5N1, H6N2, H9N2 A/duck/Hong Kong/140/1998
-T- - - - - - - I2T 1 0.1 Avian 2002 H5N1 A/duck/Fujian/13/2002
- -W- - - - - - L3W* 0 0.0 Avian H5N1 Described in ref. 7
- - -E- - - - - G4E 1 0.1 Avian 1998 H9N2 A/chicken/Anhui/1/1998
- - - -V- - - - F5V 2 0.2 Human, avian 1946, 2000 H1N1, H9N2 A/Cameron/1946
- - - -L- - - - F5L 9 0.9 Human, avian 1983–2009 H1N1, H5N2, H7N3, H11N2 A/Canterbury/236/2005
- - - - -I - - - V6I 12 1.2 Human, avian 1967–2006 H2N2, H13N6, H1N2, H3N1, H1N1 A/England/10/1967
- - - - - -Y- - F7Y 1 0.1 Human 1999 H3N2 A/New South Wales/15/1999
Total mutations 82
Total sequences 998 8.2
A B C
Fig. 1. Ex vivo immunodominance of A2-M158
+ over B35-NP418
+ CTLs. (A) Costaining of A2-M158
+ and B35-NP418
+ CTLs directly ex vivo by tetramer enrichment
showing (i) single tetramer+CD8+CD4−CD14−CD19− cells and (ii) fold-increase of the A2-M158 above the B35-NP418 CTL response. (B and C) Recognition of
naturally occurring M158 (B) and NP418 (C) variants by human PBMCs from A2
+B35+ donors was assessed 10 d after restimulation using intracellular staining for
IFN-γ production in response to the indicated peptides. Data show individual subjects (S).



















































paired with TRAV27/CDR3α-GGSQGNL (Fig. 2C and Fig. S3
C–E). In subject 23, the public TRBV19/CDR3β-SIRSSYEQ
paired with a similar TRAV27/CDR3α-ASGSSNTGKL (44% of
sequences), whereas subject 22 exhibited a limited TCRαβ repertoire
in which an alternate TCRβ (TRBV19/CDR3β-GAGGPLNEQ)
paired with a non-TRAV27TCRα (TRAV12.3/CDR3α-SERNNARL).
Public TCRαβ clonotypes can therefore be generated in the
majority of HLA-A2+ individuals across different ethnicities, in-
cluding Indigenous Australians.
Reflecting the prevalence of low-frequency private clonotypes,
the M158-specific TCRαβ repertoire was more diverse (12.4 ± 6.0
CDR3αβ pairs per donor) than previously reported. Furthermore,
the AGA(Gn)GG CDR3α motif (22) (in which “n” denotes any
number of residues) found by others following long-term culture
was not consistently present in our direct ex vivo dataset, although
two glycines (GG) featured in 20 of the 45 CDR3α sequences. The
CDR3β IRS motif, which forms the basis for “peg–notch” JM22
TCR recognition of the “plain vanilla” M158 epitope (21), was
used in 11/45 CDR3β sequences across five donors.
In contrast, analysis of the B35-NP418
+ TCR repertoire using
pooled B35-NP418 tetramers (Fig. S4) revealed distinct CDR3α/
CDR3β sequences incorporating diverse TRAV and TRBV seg-
ments. A preference for TRBV20-1/TRBJ5-1 rearrangements with
a CDR3β length of 7 or 10 amino acids was observed in the TCRβ
repertoire, whereas the predominant TCRα chains favored
TRAV8-1 and TRAJ18 with a CDR3α length of 8–10 amino
acids (Table S2). However, only one common sequence
(TRAV8-1/CDR3α-NEGGSTLGRL) was found among in-
dividuals (Fig. S4).
There was no overlap between the B35-NP418
+ TCR datasets,
generating a Morisita–Horn statistic of 1 (zero interindividual simi-
larity). However, the A2-M158
+ TCR datasets overlapped consider-
ably, driven by the public TRBV19/CDR3β-SIRSSYEQ sequence
(averaged Morisita–Horn statistic of 0.6). These differences were sta-
tistically significant (P = 0.0056, Wilcoxon signed tank test). In addi-
tion, the Simpson diversity index was higher for B35-NP418
+ TCRαβs
(0.97 ± 0.03) than for A2-M158
+ TCRαβs (0.75 ± 0.27) (Table S2).
Thus, dominant public TCRαβ clonotypes (TRBV19/TRAV27)
are selected in HLA-A*0201+ donors responding to the relatively
invariant A2-M158 epitope, whereas TCRαβ clonotypes directed
at the hypervariable B35-NP418 epitope are more diverse across
individuals.
Public M158-Specific TCRαβ Clonotypes Cross-Recognize Newly
Identified Variants. How do A2-M158
+ CTLs recognize naturally
occurring M158 variants? To investigate this question, periph-
eral blood mononuclear cells (PBMCs) were stimulated with
the mutant peptide (M1-L3W, -G4E, or -F5L) for 10 d and then
stained with the M158 WT tetramer. In this way, variant-specific
CTLs were amplified by the mutant peptide, and cross-reactive
clonotypes identified by reactivity with the M158 WT tetramer were
characterized using single-cell CDR3αβ TCR repertoire diversity
analysis (Fig. 3 and Table S3). The variant M1-L3W, M1-G4E, and
M1-F5L peptides represent naturally occurring M158 mutants, with
a CTL response magnitude hierarchy of M1-L3W >M1-F5L >M1-
G4E in subject 9 and subject 16 (Fig. 3).
The public HLA-A*0201-M158
+ TCR (CDR3α-GGSQGNL;
CDR3β-SIRSSYEQ) recognized all three peptide variants (Table
S3), although the frequency was slightly lower for the M1-G4E
mutant (47% of the WT). Higher-frequency public TCRαβ use
correlated with larger mutant-specific CTL responses (Fig. 1B), in-
dicating that public HLA-A*0201-M158
+ TCRs play an important
role in variant cross-recognition. Overall, the mutant M158 peptides
selected a TCRαβ repertoire comparable to that of WT M158
with similar TRAV27, TRAJ42, TRBV19, and TRBJ2-7 use (ex-
cept for M1-G4E in subject 16, which used TRAV23DV/6 instead
of the typically dominant TRAV27), suggesting that WT HLA-
A*0201-M158
+ TCRs are largely cross-reactive with M158 variants.
HLA Presentation and TCR Recognition of M158 Variants. To de-
termine the impact of peptide mutation on HLA binding and T-cell
recognition, we assessed the extent to which the naturally occurring
M158 mutant peptides M1-F5L, M1-G4E, and M1-L3W stabilize
HLA-A*0201. We refolded the HLA-A*0201 molecule with the
M158 peptide and each of the three variants to determine the
thermal stability of the corresponding peptide-HLA (pHLA)
complexes. In complex with the M158 peptide, HLA-A*0201
exhibited a thermal melt point (Tm, the temperature required to
unfold 50% of the protein) of ∼66 °C; the Tm was similar for the
three M158 variants (Table S4), indicating that the mutations
directly affect TCR binding rather than pHLA complex stability.
To understand the mode of recognition of M158 mutants by
public HLA-A*0201-M158
+ TCRs, we conducted surface plas-
mon resonance studies with the previously characterized M158-
specific JM22 TCR (TRAV27/CDR3α-AGSQGNL; TRBV19/
CDR3β-SSRSSYEQ) (21). We confirmed that the JM22 TCR
binds with high affinity (1.79 μM) to the HLA-A*0201-M158
complex (21, 23), but measured substantially lower affinities for
the three M158 variants (Table S5). Namely, weak binding (Kd
>200 μM) characterized the JM22 TCR interaction with M1-
G4E and M1-F5L, and this was further diminished (Kd >600 μM)
for M1-L3W, presented by HLA-A*0201 (Table S5). Thus, al-
though the JM22 TCR can recognize all M158 variants, the bind-
ing affinity is lower for the mutant epitopes (24).
M158 Variants No Longer Form Plain Vanilla Epitopes. To understand
the impact of the naturally occurring M158 mutations on epitope
presentation and T-cell recognition, we determined the struc-
tures of three binary pHLA complexes (M1-F5L, M1-G4E, and
A B
C
Fig. 2. The A2-M158
+ TCRαβ repertoire is dominated
by a public clonotype. A2-M158
+ CTLs were isolated
directly ex vivo from non-Indigenous healthy donors
(n = 5) by magnetic enrichment and flow cytometric
sorting of single tetramer+ cells. Populations were
gated on viable Dump−tetramer+CD3+CD8+ events.
(A) Representative flow cytometry profiles showing
tetramer+CD8+ T cells after ex vivo enrichment.
(B) TRBV and TRAV use. (C) Frequency of CDR3αβ
clonotypes. Corresponding data for healthy Indigenous
Australian donors (n = 3) are shown in Fig. S3. P, public.






























M1-L3W) (Fig. 4 and Table S6) and compared these structures
with the previously solved structure of HLA-A*0201-M158 (23).
The M158 epitope is considered plain vanilla because the M158
epitope adopts a flat surface in the cleft of HLA-A*0201 (25)
(Fig. 4A). Indeed, despite containing two aromatic residues (P5-
Phe and P7-Phe), these side chains are buried inside the antigen-
binding cleft, leaving the P6-Val solvent exposed. The overall
structure of the M1-G4E mutant complex is similar to that of the
M158 complex, with rmsds of 0.25 Å for the antigen-binding cleft
and 0.27 Å for the peptide (Fig. 4A). Although the replacement of
the glycine residue by glutamic acid does not disturb the backbone
conformation for M1-G4E, it allows P6-Val to move deeper into the
HLA-A*0201 antigen-binding cleft (Fig. 4A). As a result, P5-Phe
and P7-Phe are mobile and adopt several conformations, most of
which are solvent exposed (Fig. 4A).
More dramatic rearrangements were observed for the M1-L3W
(Fig. 4B) and M1-F5L (Fig. 4C) variants. The P3-Leu of the WT
M158 peptide is buried in the cleft and interacts with the B pocket
of HLA-A*0201, whereas the larger P3-Trp of M1-L3W is ac-
commodated in the B pocket without modification of the overall
antigen-binding cleft structure (rmsd of 0.33 Å). However, the
M1-L3W peptide must rearrange dramatically due to the presence
of the large tryptophan residue at P3 (rmsd of 0.61 Å) (Fig. 4B).
The P5-Phe side chain swings out of the antigen-binding cleft to
avoid steric clashes with P3-Trp and hence becomes solvent ex-
posed. As a consequence, P6-Val is buried in the antigen-binding
cleft, and P7-Phe is again mobile and solvent exposed (Fig. 4B).
Thus, in the HLA-A*0201-M1-L3W structure, the two large
aromatic side chains at P5 and P7 are directly available for
TCR interaction.
Similarly, the M1-F5L variant adopts a different peptide con-
formation (rmsd of 0.44 Å) without distorting the antigen-binding
cleft (rmsd of 0.29 Å) (Fig. 4C). Even though P5-Leu is smaller
than P5-Phe, the rotamer of the leucine side chain (like P5-Phe)
does not allow docking inside the antigen-binding cleft without
changing the overall backbone of the peptide. The P3-Leu
therefore no longer interacts with the B pocket of HLA-A*0201
and instead becomes mobile and solvent exposed. The new con-
formation of the P5-Leu residue also impacts the P6-Val confor-
mation, which becomes buried in the antigen-binding cleft,
whereas P7-Phe is now solvent exposed and mobile (Fig. 4C).
Overall, these surprising structures of the M158 variants dem-
onstrate that interplay between peptide residues constrains the
conformation of the M158 epitope, with any alterations reflecting
either the inherent flexibility of particular residues (in M1-G4E
and M1-F5L) or steric hindrance (in M1-L3W). As a consequence,
single substitutions at different positions in the peptide can trans-
form the plain vanilla M158 epitope into a more featured antigen.
The Public JM22 TCR Recognizes M158 Variants via Induced-Fit
Molecular Mimicry. To understand how HLA-A*0201-M158
+ CTLs
recognize the naturally occurring epitope variants (Fig. 1B), we
determined the structures of the JM22 TCR (21) in complex with
HLA-A*0201-M1-G4E and HLA-A*0201-M1-F5L (Table S7).
As in the WT M158 complex (Fig. 4 D–F), the JM22 TCR docks
orthogonally on the two M158 variant peptides presented by
HLA-A*0201 (rmsd of 1.1 Å and 0.7 Å with the M1-G4E and
M1-F5L complexes, respectively). The M1-G4E and M1-F5L pep-
tides change conformation upon JM22 TCR binding (Fig. 4 G and
H) to mimic that of the WTM158 peptide (Fig. 4I). These structural
rearrangements allow key residues (23) from the JM22 TCR β-chain
(identified via mutagenesis), namely D32, Q52, and R98, to main-
tain critical interactions with both the peptide and HLA-A*0201.
The requirement for conformational change also explains why the
JM22 TCR binds HLA-A*0201-M1-G4E and HLA-A*0201-M1-
F5L with lower affinities than HLA-A*0201-M158 (Fig. 4G andH).
The leucine substitution at p5 (M1-F5L) is accommodated with-
out rearrangements of the JM22 TCR CDR loops (Fig. 4J) (23),
whereas the JM22 TCR docking angle is slightly different when in
complex with M158 and M1-G4E (78° and 80°, respectively) (Fig. 4
D and F). This difference is a direct result of the P4-Glu substitution,
which causes a 1-Å shift of the CDR3α loop to avoid steric clashes
with the P4-Glu (Fig. 4K). The key JM22 TCR β-chain residues
identified via mutagenesis (23), namely D32, Q52, and R98, con-
serve their critical interactions with both the peptide and the HLA
molecule despite the P4-Glu and P5-Leu substitutions. Thus, the
lower affinity of the JM22 TCR for HLA-A*0201-M1-F5L and
HLA-A*0201-M1-G4E can be attributed to structural changes in
the corresponding peptides, as well as to the CDR3α loop in the
case of M1-G4E, following TCR binding (Fig. 4 G and H, re-
spectively). Given the structural rearrangement of the M1-G4E and
M1-F5L peptides, it is anticipated that large changes would occur in
the M1-L3W peptide, resulting in an even lower affinity for the
JM22 TCR (Table S5).
These ternary structures show that a public TCRαβ can recog-
nize naturally occurring M158 variants via induced-fit molecular
mimicry, potentially explaining why this epitope is conserved among
influenza viruses circulating in the human population.
Discussion
Diversity in the TCR repertoire has been associated with high-
avidity recognition of MHC-peptide antigens, effective viral clear-
ance, and the containment of immune escape (26, 27). In this study,
we used a multiplex single-cell RT-PCR (28, 29) to determine
whether TCRαβ diversity and/or composition are associated with
immune escape in influenza virus infection. The broad recognition
spectrum of a public TRAV27/TRBV19+ TCR within the M158-
specific CTL repertoire correlated with the relative scarcity of
naturally occurring epitope variants. Such public A2-M158
+ TCRs
were found to be highly prevalent across donors, including HLA-
A*0201+ non-Indigenous donors and Indigenous Australians
(HLA-A*0201 frequency of 30–50% and 10–15%, respectively). It
is notable in this regard that Indigenous Australians are at greater
risk of severe influenza disease, especially when new IAVs emerge
(9, 30, 31). Nonetheless, preexisting CTL memory characterized by
best-fit public TCRs may confer protection in the context of
HLA-A*0201.
The ternary structure of a public TCR bound to the plain vanilla
HLA-A*0201-M158 complex (21, 23) showed previously that the
central arginine residue within the predominant CDR3β IRS motif
(21) is required to allow a peg–notch interaction. We extended this
analysis to naturally occurring M158 mutants and found that the
A
B
Fig. 3. The A2-M158
+ TCRαβ repertoire cross-recog-
nizes M158 peptide variants. (A) A2
+ PBMCs were
restimulated for 10 d in vitro with the M158 variant
peptides M1-G4E, M1-F5L, or M1-L3W and then stained
with the M158 WT tetramer. Thus, TCRs were selected
to recognize the mutant by the 10-d restimulation and
to recognize the cross-reactive WT epitope by tetramer
sort. Representative flow cytometry plots are shown
gated on CD8+ T cells after the exclusion of CD4+CD14+
CD19+ events. (B) Summary of public TCRαβ use.


















































same public TCR can recognize naturally occurring variants via
induced-fit molecular mimicry, incurring a penalty in terms of
binding affinity and T-cell activation. Moreover, the extent of
variant recognition correlated with the prevalence of public TCRs,
possibly explaining the hierarchical differences in TCR affinity
(G4E/F5L > L3W) and T-cell activation (L3W > F5L > G4E).
Donors with prominent public TCR use (e.g., subject 9, 67%)
recognized the majority of M158 mutants, and the converse was
true for donors with limited public TCR use (e.g., subject 16,
15%). These observations suggest that public TCRs may limit, at
least to some extent, the establishment of mutant strains within
the circulating pool of human IAVs. This idea is consistent with an
earlier report in which public Mamu-A*01-CM9181–specific TCRs
were shown to predict the outcome of simian immunodeficiency
virus infection in rhesus macaques (32).
Mutant peptides incorporating substitutions at TCR contact
sites within the B35-NP418 epitope (reflecting nine decades of
natural selection) can be recognized by at least two distinct sets
of cross-reactive CTLs specific for either ER or DK motifs at
P4-5 (11). In theory, accurate identification of the key solvent-
exposed residues and motifs that allow variable peptides to elicit
cross-reactive CTL responses could inform the development of
rationally designed peptide-mosaic vaccines against unpredicted
IAVs (1, 33). Unlike the A2-M158
+ CDR3αβ repertoire, how-
ever, the NP418
+ CDR3αβ repertoire in B7+ and B35+ donors is
diverse and private, potentially facilitating the emergence of novel
NP418 variants. In turn, these mutated epitopes will likely elicit de
novo TCR repertoires. Successive waves of variant exposure and
diverse TCR recruitment may therefore favor the emergence and
perpetuation of NP418 mutant IAVs (34).
Structural analyses revealed that single-amino acid substitutions
within the M158 peptide can transform this rather flat epitope into
conformations that are no longer plain vanilla (25). Although the
featureless morphology of HLA-A*0201-M158 determines the
character of the highly biased TCR repertoire (21, 25), our data show
that structurally prominent M158 variants select a similar array of
TCRs. This counterintuitive finding can be explained, at least in part,
by the observation that public TCRs (exemplified by JM22) can re-
shape such variants into conformations that resemble the WT M158
epitope, which is optimal for immediate binding without the need for
structural rearrangements. Such induced-fit molecular mimicry was
reported previously for an Epstein–Barr virus-specific TCR (35).
In summary, we show here that HLA-A*0201–restricted public
TCR clonotypes elicited by the WT M158 epitope can cross-
recognize naturally occurring peptide variants. Conversely, the
HLA-B*3501–restricted NP418 epitope selects a diverse and
largely private CDR3αβ repertoire, which correlates with fre-
quent mutational escape and the ongoing circulation of variant
IAVs (12, 16). The ability of vaccine-induced CTL responses to
protect against variable pathogens should therefore be consid-
ered in the context of individual peptides and individual TCRs.
Methods
PBMC Isolation. PBMCs were processed and HLA-typed from randomly selected
buffy packs (Melbourne Blood Bank) and healthy donors, with informedwritten
consent (Table S1). Experiments conformed to the National Health and Medical









Fig. 4. Structural analysis of M158 variants in complex with HLA-A*0201 and the JM22 TCR. (A–C) HLA-A*0201 is represented as a white cartoon with the
peptide in stick form (M158 in white, M1-G4E in orange, M1-L3W in green, M1-F5L in pink). The glycine Cα is represented as a sphere. (D–F) The JM22 TCR
footprint on the surface of HLA-A*0201 (white) in complex with M158 (D), M1-F5L (E), and M1-G4E (F) peptide (gray). The HLA and peptide atoms are colored
teal, green, and purple when contacted by CDR1α, CDR2α, and CDR3α, respectively, and red, orange, and yellow when contacted by CDR1β, CDR2β, and
CDR3β, respectively. The black spheres represent the JM22 TCR center of mass for the Vα and Vβ domains. (G) Superimposition of HLA-A*0201-M1-F5L free
(pink) and bound to the JM22 TCR (blue). (H) Superimposition of HLA-A*0201-M1-G4E free (orange) and bound to the JM22 TCR (red). (I) Superimposition of
HLA-A*0201-M158 (gray), HLA-A*0201-M1-F5L (blue), and HLA-A*0201-M1-G4E (red) bound to the JM22 TCR. (J and K) Superimposition of JM22 TCR-HLA-
A*0201-M158 (dark gray) with the JM22 TCR-HLA-A*0201-M1-F5L (blue) and JM22 TCR-HLA-A*0201-M1-G4E (red) complexes.






























Melbourne Human Research Ethics Committee and the Human Research Ethics
Committee of the Northern Territory Department of Health and Menzies
School of Health Research.
Ex Vivo Tetramer Enrichment and Phenotypic Analysis. Lymphocytes (1–8×106)
were stained with HLA-A*0201-M158 or HLA-B*3501-NP418 tetramers conju-
gated to phycoerythrin (PE) or PE-Cy7. The NP418 response was represented
by the 1918 (LPFERATIM), 1934 (LPFDRTTIM), 1947 (LPFDKTTIM), 1980
(LPFEKSTVM), and 2002 (LPFEKSTIM) variants (12). Samples were incubated
with anti-PE microbeads and tetramer-PE/PE-Cy7+ cells were enriched via mag-
netic separation (36), then stained with anti–CD4-APC-H7, anti–CD8-PerCP-Cy5.5,
anti–CD14-APC-Cy7, anti–CD19-APC-Cy7, anti–CD27-APC, and anti–CD45RA-FITC
for 30 min, washed, resuspended, and analyzed/sorted by flow cytometry.
Single-Cell Multiplex RT-PCR. Single tetramer+CD8+CD4−CD14−CD19− cells were
sorted using a FACSAria (BD Biosciences) into 96-well plates. CDR3αβ regions
were determined using a single-cell multiplex RT-PCR (28, 29). Sequences were
analyzed with FinchTV, and V/J regions were identified by IMGT.
Intracellular Cytokine Staining (ICS). PBMCs were stimulated with peptides for
10 d, and IAV-specific CTLs were quantified using IFN-γ/TNF-α ICS (12, 33). C1R-
A*0201 cells, HLA-B*0702+ PBMCs, or C1R-B*3501 cells were used to present
antigen. Mouse spleen and bronchoalveolar lavage (BAL) cells were stimulated
with M158 (GILGFVFTL), PA46 (FMYSDFHFI), or NS122 (AIMDKKIIL) for 5 h (17).
HLA-A2.1 Transgenic HHD Mice and de Novo IAV Epitope Mutations. HLA-A2.1
transgenic HHD mice were developed by François Lemonnier (37) and
provided by the Pasteur Institute. Experiments were approved by the Uni-
versity of Melbourne Animal Ethics Experimentation Committee. Mice were
lightly anesthetized and infected with 103 pfu HK (H3N2) virus intranasally.
Viral RNA was extracted from lungs 15 d after infection and reverse tran-
scribed to cDNA (17). The M1 region was amplified and sequenced.
Recombinant Influenza Viruses. Influenza viruses with amino acid substitutions
in the M158 peptide (M1-I2M, M1-F5L, M1-V6I, and M1-F7Y) were generated
using reverse genetics and amplified in embryonated eggs (38).
Protein chemistry and structural biology are described in SI Methods.
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